Medicine
Dutasteride
Dual 5-alpha reductase inhibitor (types I and II)
Evidence: 6 articles
Goals: 2
Mechanism of Action
Dutasteride is a potent, dual inhibitor of both type I and type II 5-alpha-reductase enzymes. Unlike finasteride (type II selective), dutasteride reduces DHT levels by approximately 90-95% by blocking both isoforms. Type I 5AR is expressed in skin, brain, and liver, while type II is expressed in prostate and hair follicles. The broader inhibition profile results in more complete DHT suppression, studied for benign prostatic hyperplasia and androgenic alopecia in research contexts.
Evidence Level
Clinical Trial - Human
6 studies published
Studied For
Pharmacology
Molecular Weight
528.5 g/mol
Half-Life
Approximately 5 weeks (terminal); steady state reached after 6 months
Bioavailability
Approximately 60% oral bioavailability